ReferenceRRK6020

ORION-3

An open label active comparator extension trial to assess the effect of long term dosing of inclisiran and evolocumab given as subcutaneous injections in subjects with high cardiovascular risk and elevated LDL-C (ORION-3)

Research Summary

Research Overview
PI Name Dawson - C
Speciality
Project Status Open
Proposed End Date 30/06/2021
Study Run through CRF? No
Target number of patients agreed to recruit 9
Recruitment so far 7